Safety Population
description
Transcript of Safety Population
1
CerticanCertican (everolimus) tablets (everolimus) tabletsProphylaxis of Rejection in Heart TransplantationProphylaxis of Rejection in Heart Transplantation
New Drug Application 21-628New Drug Application 21-628
Cardiovascular and Renal Drugs Advisory Committee Cardiovascular and Renal Drugs Advisory Committee November 16, 2005November 16, 2005
Clinical Safety ReviewClinical Safety Review
Arturo Hernandez, M.D. Arturo Hernandez, M.D. Marc Cavaille-Coll, M.D., Ph.D.Marc Cavaille-Coll, M.D., Ph.D.
Division of Special Pathogen and Transplant ProductsDivision of Special Pathogen and Transplant ProductsCenter for Drug Evaluation and ResearchCenter for Drug Evaluation and Research
Food and Drug AdministrationFood and Drug Administration
CerticanCertican (everolimus) tablets (everolimus) tabletsProphylaxis of Rejection in Heart TransplantationProphylaxis of Rejection in Heart Transplantation
New Drug Application 21-628New Drug Application 21-628
Cardiovascular and Renal Drugs Advisory Committee Cardiovascular and Renal Drugs Advisory Committee November 16, 2005November 16, 2005
Clinical Safety ReviewClinical Safety Review
Arturo Hernandez, M.D. Arturo Hernandez, M.D. Marc Cavaille-Coll, M.D., Ph.D.Marc Cavaille-Coll, M.D., Ph.D.
Division of Special Pathogen and Transplant ProductsDivision of Special Pathogen and Transplant ProductsCenter for Drug Evaluation and ResearchCenter for Drug Evaluation and Research
Food and Drug AdministrationFood and Drug Administration
2
Safety PopulationSafety PopulationSafety PopulationSafety Population
• All subjects who received at least one dose of study medication: RAD* 1.5 mg, n=209; RAD 3 mg, n=211; AZA, n=214.
• Adverse events were reported while subjects were still on study medication, serious adverse events while subjects were still on study medication and up to 30 days after discontinuation.
• All subjects who received at least one dose of study medication: RAD* 1.5 mg, n=209; RAD 3 mg, n=211; AZA, n=214.
• Adverse events were reported while subjects were still on study medication, serious adverse events while subjects were still on study medication and up to 30 days after discontinuation.
*RAD = Certican (everolimus)
3
Targeted and Achieved Trough Targeted and Achieved Trough Cyclosporine Concentrations in Cyclosporine Concentrations in
Study B253Study B253
Targeted and Achieved Trough Targeted and Achieved Trough Cyclosporine Concentrations in Cyclosporine Concentrations in
Study B253Study B253
0 1 2 3 4 5 6 7 8 9 10 11 120
50
100
150
200
250
300
350
400
Azathioprine Control
ERL 0.75 mg b.i.d.Lower Limit
ERL 1.5 mg b.i.d.
Upper Limit
Time Post Transplant (month)
Cy
clo
sp
ori
ne
Cm
in (
ng
/mL
)
0 1 2 3 4 5 6 7 8 9 10 11 120
50
100
150
200
250
300
350
400
Azathioprine Control
ERL 0.75 mg b.i.d.Lower Limit
ERL 1.5 mg b.i.d.
Upper Limit
Time Post Transplant (month)
Cy
clo
sp
ori
ne
Cm
in (
ng
/mL
)
4
Concomitant Administration of Concomitant Administration of Immunosuppressive Agents Other Immunosuppressive Agents Other than Randomized Study Medication than Randomized Study Medication
and Neoral by WHO Preferred Drug Nameand Neoral by WHO Preferred Drug Name(ITT Population - 24 Month Analysis)(ITT Population - 24 Month Analysis)
Concomitant Administration of Concomitant Administration of Immunosuppressive Agents Other Immunosuppressive Agents Other than Randomized Study Medication than Randomized Study Medication
and Neoral by WHO Preferred Drug Nameand Neoral by WHO Preferred Drug Name(ITT Population - 24 Month Analysis)(ITT Population - 24 Month Analysis)
RAD 1.5 (n=209)
RAD 3(n=211)
AZA(n=214)
Methylprednisolone Total
160 (76.5%)
142 (67%)
170 (79%)
Antibody Therapy Total
86(41%)
83 (39%)
95 (44%)
5
Premature Discontinuation from Study Medication Premature Discontinuation from Study Medication (Safety population - 12 and 24 Month Visits)(Safety population - 12 and 24 Month Visits)
Premature Discontinuation from Study Medication Premature Discontinuation from Study Medication (Safety population - 12 and 24 Month Visits)(Safety population - 12 and 24 Month Visits)
RAD 1.5(n=209)
RAD 3(n=211)
AZA(n=214)
12 month visit Time window: 312 - 415
days
Adverse events
62 (29.7%)
33(53.2%)
84 (39.8%)
46(54.8%)
61 (28.5%)
28(45.9%)
24 month visitTime window: up to 810 days
82 (39.2%)
104 (49.3%)
83 (38.8%)
Adverse events 43
(52.4%)58
(55.8%)40
(48.2%)
6
Patients Who Discontinue Study MedicationPatients Who Discontinue Study Medication(24 Months, Safety Population)(24 Months, Safety Population)
Study B253Study B253
Patients Who Discontinue Study MedicationPatients Who Discontinue Study Medication(24 Months, Safety Population)(24 Months, Safety Population)
Study B253Study B253
Reason for Discontinuation from Study Medication
RAD 1.5 mg (n=209)
RAD 3 mg(n=211)
AZA(n=214)
Adverse events 43 (52%) 58 (56%) 40 (48%)
Abnormal laboratory value(s) 9 (11%) 18 (17%) 10 (12%)
Unsatisfactory therapeutic effect
15 (18%) 3 (3%) 18 (22%)
Withdrawn consent 6 (7%) 11 (11%) 3 (4%)
Death 7 (5%) 9 (9%) 7 (8%)
Total Discontinuation from Study Medication
82 (39%) 104 (49%) 83 (39%)
7
Dose Reductions from Study Medication Dose Reductions from Study Medication (Safety Population - 24 months analysis)(Safety Population - 24 months analysis)
Dose Reductions from Study Medication Dose Reductions from Study Medication (Safety Population - 24 months analysis)(Safety Population - 24 months analysis)
RAD 1.5 mg (n= 209)
RAD 3 mg (n=211)
AZA(n=214)
Any Dose Reduction Total 121(58%)
134(64%)
112(52%)
Adverse Event 56
(26.8%)68
(32.2%)20
(9.3%)
WBC Abnormality 51
(24.4%)58
(27.5%)71
(33.2%)
Platelet Abnormality 22
(10.5%)25
(11.8%)3
(1.4%)
8
Post Heart Transplant Morbidity in Post Heart Transplant Morbidity in the Safety Populationthe Safety Population
Post Heart Transplant Morbidity in Post Heart Transplant Morbidity in the Safety Populationthe Safety Population
• Morbidity associated with immunosuppression: infections, pneumonia
• Morbidity potentially associated with antiproliferative effect of mTOR inhibition: wound site complications, gastrointestinal hemorrhage, bone marrow effects, lymphocele, pericardial and pleural complications.
• Morbidity potentially associated with the concurrent use of mTOR inhibitors and cyclosporine: lipid abnormalities, HUS, renal function impairment.
• Morbidity associated with immunosuppression: infections, pneumonia
• Morbidity potentially associated with antiproliferative effect of mTOR inhibition: wound site complications, gastrointestinal hemorrhage, bone marrow effects, lymphocele, pericardial and pleural complications.
• Morbidity potentially associated with the concurrent use of mTOR inhibitors and cyclosporine: lipid abnormalities, HUS, renal function impairment.
9
Infections: Safety Population - 24 Infections: Safety Population - 24 Month AnalysisMonth Analysis
Infections: Safety Population - 24 Infections: Safety Population - 24 Month AnalysisMonth Analysis
Type of Organism or preferred term
RAD 1.5 (n=209)
RAD 3(n=211)
AZA(n=214)
Any Infection 160 (77%)
169 (80%)
154 (72%)
Bacterial 78 (37%) 85 (40%) 55 (26%)
Fungal 18 (9%) 27 (13%) 19 (9%)
Viral 34 (16 %) 39 (19%) 69 (32%)
CMV infection 15 (7%) 15 (7%) 45 (21%)
Herpes simplex 17 (8%) 12 (6%) 23 (11%)
10
Pneumonias Pneumonias (Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Pneumonias Pneumonias (Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Preferred Term RAD 1.5 mg (n=209)
RAD 3 mg(n=211)
AZA(n=214)
Pneumonia NOS (AE) 29 (14%) 20 (10%) 6 (3%)
Bacterial pneumonia (AE) 12(6%) 9 (4%) 3 (1%)
All types of pneumonia (AE)
47 (23%) 38 (18%) 11 (5%)
Pneumonia (Severe ) 13 (6%) 21 (10%) 4 (2%)
Pneumonia (DAE*) 1 (0.5%) 6(3%) 2 (1%)
Pneumonia (NSAE**) 33 (16%) 36 (17%) 11(5%)
*DAE=discontinued due to AE (adverse event)
**NSAE=non-fatal SAE (serious adverse event)
11
Wound Site Related ComplicationsWound Site Related Complications (Safety Population - 24 Month Analysis) (Safety Population - 24 Month Analysis)
Wound Site Related ComplicationsWound Site Related Complications (Safety Population - 24 Month Analysis) (Safety Population - 24 Month Analysis)
Preferred Term RAD 1.5 (n= 209)
RAD 3(n=211)
AZA(n=214)
Wound infection(AE) 15 (7%) 11 (5%) 6 (3%)
(NSAE) 9 (4%) 7 (3%) 5 (2%)
Wound dehiscence / wound complication NOS (NSAE)
4 (2%) 5 (2%) 1(0.5%)
Incisional hernia nos (AE) 9 (4%) 8 (4%) 3 (1%)
Lymphocele (AE) 10 (5%) 9 (4%) 2 (1%)
(NSAE) 2 ( 1.0%) 3 (1.4%) 0
Pleural Effusion (NSAE) 4 ( 2%) 9 (4%) 2 ( 1%)
12
Pericardial ComplicationsPericardial Complications(Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Pericardial ComplicationsPericardial Complications(Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
System Organ Classification or Preferred Term
RAD 1.5 (n= 209)
RAD 3(n=211)
AZA(n=214)
Pericardial effusion (AE) 48 (23%) 49 (23%) 36 (17%)
(NSAE) 22 (11%) 16 (8%) 6 (3%)
Cardiac tamponade (AE) 6 (3%) 10 (5%) 3 (1%)
(NSAE) 4 (2%) 9 (4%) 3 (1%)
Pericarditis* (NSAE) 2 (1%) 5 (2%) 2 (1%)
Mediastinitis (NSAE) 5 (2%) 6 ( 3%) 3 (1%)
13
Gastrointestinal Hemorrhage Gastrointestinal Hemorrhage (Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Gastrointestinal Hemorrhage Gastrointestinal Hemorrhage (Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Preferred Term RAD 1.5 (n=209)
RAD 3(n=211)
AZA(n=214)
GI HEMORRHAGE TOTAL (AE) 7 (3%) 16 (8%) 4 (2%)
Gastrointestinal hemorrhage NOS (AE) 2 (1 %) 9 (4%) 3 (1%)
(NSAE) 2 (1.0%) 5 (2.4%) 1 (0.5%)
(DAE) 0 3 (1%)* 0
Gastric ulcer hemorrhage and Hemorrhagic Gastritis
(AE) 3 (1%) 4 (2%) 0
(NSAE) 2 1 0
* One patient died from this cause
14
Hematological ToxicitiesHematological Toxicities(Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Hematological ToxicitiesHematological Toxicities(Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Preferred Term RAD 1.5 (n=209)
RAD 3(n=211)
AZA(n=214)
Anemia NOS AE 70 (34%) 93 (44%) 58 (27%)
DAE 0 5 (2%) 1 (0.5%)
NSAE 6 (2.9%) 17 (8%) 8 (4%)
Leukopenia NOS AE 43 (21%) 44 (21%) 63 (29%)
DAE 4 (2%) 5 (2%) 7 (3%)
NSAE 1 (0.5%) 4 (2%) 5 (2%)
Thrombocytopenia AE 21 (10%) 37 (18%) 16(8%)
DAE 1 (0.5%) 4 (2%) 1 (0.5%)
NSAE 1 (0.5%) 1 (0.5%) 0
15
Mean Hemoglobin [g/dL] and Mean Hemoglobin [g/dL] and Mean Leukocyte count [10^9 /L] by Visit Mean Leukocyte count [10^9 /L] by Visit (Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Mean Hemoglobin [g/dL] and Mean Hemoglobin [g/dL] and Mean Leukocyte count [10^9 /L] by Visit Mean Leukocyte count [10^9 /L] by Visit (Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
5
6
7
8
9
10
11
12
13
14
15
Leuc
ocyt
es [1
0^9
/L]
0 3 6 9 12 15 18 21 24
Months Post-transplantation
Y RAD 1.5 RAD 3 AZA
9.5
10
10.5
11
11.5
12
12.5
13
Hem
oglo
bin
g/dL
0 3 6 9 12 15 18 21 24
Months Post-transplantation
16
Lipid AbnormalitiesLipid AbnormalitiesMean Mean TriglyceridesTriglycerides and and CholesterolCholesterol [mmol/L] by [mmol/L] by
Visit (Safety Population - 24 Month Analysis)Visit (Safety Population - 24 Month Analysis)
Lipid AbnormalitiesLipid AbnormalitiesMean Mean TriglyceridesTriglycerides and and CholesterolCholesterol [mmol/L] by [mmol/L] by
Visit (Safety Population - 24 Month Analysis)Visit (Safety Population - 24 Month Analysis)
1
1.4
1.8
2.22.4
2.8
3.23.4
Trigly
cerides m
mol/L
0 3 6 9 12 15 18 21 24
Months Post-transplantation
3
3.4
3.8
4.2
4.6
5
5.4
5.8
6.2
Cho
lest
erol
mm
ol/L
0 3 6 9 12 15 18 21 24
Months Post-transplantation
Y RAD 1.5 RAD 3 AZA
17
Mean Cockcroft-Gault Calculated Creatinine Mean Cockcroft-Gault Calculated Creatinine Clearance Study B253 Clearance Study B253
(Safety Population - 24-Month Analysis)(Safety Population - 24-Month Analysis)
Mean Cockcroft-Gault Calculated Creatinine Mean Cockcroft-Gault Calculated Creatinine Clearance Study B253 Clearance Study B253
(Safety Population - 24-Month Analysis)(Safety Population - 24-Month Analysis)
45
50
55
60
65
70
75C
reatinin
e C
leara
nce m
L/m
in
0 3 6 9 12 15 18 21 24
Months Post-transplantation
Y RAD 1.5 RAD 3 AZA
18
Mean Cockcroft-Gault calculated Creatinine Mean Cockcroft-Gault calculated Creatinine Clearance Study B253 Clearance Study B253
(Safety Population - 24-Month Analysis)(Safety Population - 24-Month Analysis)
Mean Cockcroft-Gault calculated Creatinine Mean Cockcroft-Gault calculated Creatinine Clearance Study B253 Clearance Study B253
(Safety Population - 24-Month Analysis)(Safety Population - 24-Month Analysis)
Y RAD 1.5 RAD 3 AZA
50
52
54
56
58
60
62
64
66
68
70
72C
alc
ula
ted C
rC
l m
L/m
in
-1 0 1 2 3 4 5 6
Months Post-transplantation
19
Estimated Mean Creatinine Clearance Estimated Mean Creatinine Clearance (mL/min) Change from Baseline (mL/min) Change from Baseline
(Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
Estimated Mean Creatinine Clearance Estimated Mean Creatinine Clearance (mL/min) Change from Baseline (mL/min) Change from Baseline
(Safety Population - 24 Month Analysis)(Safety Population - 24 Month Analysis)
-20
-15
-10
-5
0
5C
hange in C
rC
l fr
om
BL m
L/m
in
0 3 6 9 12 15 18 21 24
Months Post-transplantation
Y Change RAD 1.5 Change RAD 3
Change AZA
20
Study B253 and ISHLT Registry Data Study B253 and ISHLT Registry Data Percentage of Patients with Creatinine Percentage of Patients with Creatinine 2.5 mg/dL 2.5 mg/dL
Study B253 and ISHLT Registry Data Study B253 and ISHLT Registry Data Percentage of Patients with Creatinine Percentage of Patients with Creatinine 2.5 mg/dL 2.5 mg/dL
9.1 7.87.7
0.0
5.0
10.0
15.0
20.0
25.0
30.0
B-253 IS HLT 04/94to 12/99
IS HLT 01/00to 06/03
Per
cen
tag
e o
f P
atie
nts
O
bse
rved
Ever 1.5 m g
Ever 3.0 m g
AZA
21
Summary / ConclusionsSummary / ConclusionsSummary / ConclusionsSummary / Conclusions
• The impact of full dose cyclosporine plus everolimus on renal function impairment was early and persistent, and may not be reversible if renal toxicity is sustained for a period of time sufficient to allow irreversible changes to take place.
• Complications potentially related to antiproliferative effects of everolimus such as wound healing problems, pericardial complications and gastrointestinal bleeding were also more common in the everolimus arms.
• The impact of full dose cyclosporine plus everolimus on renal function impairment was early and persistent, and may not be reversible if renal toxicity is sustained for a period of time sufficient to allow irreversible changes to take place.
• Complications potentially related to antiproliferative effects of everolimus such as wound healing problems, pericardial complications and gastrointestinal bleeding were also more common in the everolimus arms.
22
Summary / ConclusionsSummary / ConclusionsSummary / ConclusionsSummary / Conclusions
• Pneumonias were more frequently observed in the everolimus arms.
• Dyslipidemias occurred early or worsen after drug exposure and persisted despite the use of statins and attempts to optimize lipid lowering therapy.
• Pneumonias were more frequently observed in the everolimus arms.
• Dyslipidemias occurred early or worsen after drug exposure and persisted despite the use of statins and attempts to optimize lipid lowering therapy.
23
Summary / ConclusionsSummary / ConclusionsSummary / ConclusionsSummary / Conclusions
• Overall, the potential risks associated with the use of the everolimus-cyclosporine combinations studied in B-253 were felt to outweigh the potential benefits.
• There is a need to develop regimens that could minimize these toxicities while providing adequate protection against allograft rejection.
• Overall, the potential risks associated with the use of the everolimus-cyclosporine combinations studied in B-253 were felt to outweigh the potential benefits.
• There is a need to develop regimens that could minimize these toxicities while providing adequate protection against allograft rejection.
24
25
Lipid AbnormalitiesLipid AbnormalitiesMean Low Density Lipoprotein [mmol/L] by VisitMean Low Density Lipoprotein [mmol/L] by Visit(B-253 Safety Population - 24 Month Analysis)(B-253 Safety Population - 24 Month Analysis)
Lipid AbnormalitiesLipid AbnormalitiesMean Low Density Lipoprotein [mmol/L] by VisitMean Low Density Lipoprotein [mmol/L] by Visit(B-253 Safety Population - 24 Month Analysis)(B-253 Safety Population - 24 Month Analysis)
2.7
2.8
2.9
3
3.1
3.2
3.3
Low
Density
Lip
opro
tein
[m
mol/L
]
0 5 10 15 20 25
Months Post-transplantation
116 mg/dl
108 mg/dL
120 mg/dL
Y RAD 1.5 RAD 3 AZA
1.5
1.7
1.9
2.1
2.3
2.5
2.7
2.9
3.1
3.3
3.5
Low
Density
Lip
opro
tein
[m
mol/L
]
-5 0 5 10 15 20 25 30
Months Post-transplantation